Philip C. Strassburger
Net Worth

Last updated:

What is Philip C. Strassburger net worth?

The estimated net worth of Mr. Philip C. Strassburger is at least $2,615,067 as of 5 Feb 2024. He owns shares worth $1,960,525 as insider, has earned $89,322 from insider trading and has received compensation worth at least $565,220 in Ocular Therapeutix, Inc..

What is the salary of Philip C. Strassburger?

Mr. Philip C. Strassburger salary is $282,610 per year as Gen. Counsel in Ocular Therapeutix, Inc..

How old is Philip C. Strassburger?

Mr. Philip C. Strassburger is 65 years old, born in 1960.

What stocks does Philip C. Strassburger currently own?

As insider, Mr. Philip C. Strassburger owns shares in one company:

Company Title Shares Price per share Total value
Ocular Therapeutix, Inc. (OCUL) Gen. Counsel 161,493 $12.14 $1,960,525

What does Ocular Therapeutix, Inc. do?

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Philip C. Strassburger insider trading

Ocular Therapeutix, Inc.

Mr. Philip C. Strassburger has made 3 insider trades between 2023-2024, according to the Form 4 filled with the SEC. Most recently he sold 6,029 units of OCUL stock worth $29,301 on 5 Feb 2024.

The largest trade he's ever made was exercising 6,831 units of OCUL stock on 31 Jan 2024. As of 5 Feb 2024 he still owns at least 161,493 units of OCUL stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 6,029 $4.86 $29,301
Sale
Common Stock 6,831 $4.95 $33,813
Sale
Common Stock 6,181 $4.24 $26,207

Ocular Therapeutix key executives

Ocular Therapeutix, Inc. executives and other stock owners filed with the SEC: